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Accelerated high-frequency repetitive transcranial magnetic stimulation (aHF-rTMS) was proven to produce
fast clinical effects in humans suffering from psychiatric illnesses. Although dogs also frequently present
behavioral symptoms similar to mental illness, rTMS treatment was not yet investigated in this species. The
aim of this study was to apply an aHF-rTMS treatment over the frontal cortex in an anxious aggressive dog.
Because aHF-rTMS is used to treat anxiety and mood disorders in humans and shows changes in neuronal
activity and onmonoamine concentrations, it was hypothesized that the dog’s behaviorwould improve after
sucha treatment. This improvementwasexpected tobeaccompaniedbyalterations inregionalcerebralblood
ﬂow (rCBF) aswell as inmonoamine levels in cerebrospinalﬂuid (CSF) and serum.An aHF-rTMSprotocolwas
applied twice (3weeks separated)over the left frontal cortex (5sessions, 20Hz,110%corticalmotor threshold)
in a 5-year-old neuteredmale BelgianMalinois dog showing anxious aggressive behavior. Each protocol was
preceded and followedbya behavior assessment and ad,1 hexamethylpropylene amineoxime single-photon
emission computed tomography scan. A Z-score for each volume of interest at each time point was obtained,
whereby a jZj-score > 3.09 (P-value of 0.001) indicated signiﬁcant differences. Monoamines and their me-
tabolites were quantiﬁed in CSF and serum using liquid chromatography coupled to electrochemical detec-
tion. An improvement of the dog’s aggressive behaviorwas detected. At baseline, only a decreased rCBFof the
left frontal cortexwasnoticeable (Z-score¼3.87).Twenty-fourhoursafter theﬁrstprotocol, theperfusion in
the left frontal cortex was normalized and decreased in subcortical region (Z-score ¼ 6.97). Three weeks
after each stimulation protocol, no deviations in the rCBF were found. Parallel time-dependent changes of
3,4-dihydroxyphenylacetic acid (DOPAC) concentrations in serum and CSF were observed. This case study
demonstrates that a single day aHF-rTMS treatment reduces a dog’s anxious/aggressive behavior. This
behavioral change was accompanied by immediate and long-lasting alterations in the rCBF and DOPAC
concentration. This study conﬁrms the interaction between the frontal cortex and the subcortical region in
canine anxiety. Finally, DOPAC is put forward as a possible biomarker for the improvement of this behavior.
 2019 Published by Elsevier Inc.Case presentation
A 5-year-old neutered male white-coated Malinois dog (32 kg)
was presented with anxious aggressive behavior.Department of Psychiatry and
P) lab, Faculty of Medicine and
elgium. Tel.: 0032 47147 0117.
kx).History and presenting signs
The patient is, together with its 16 siblings, the accidental
offspring between its half-brother and its mother. Neither parent
showed behavioral problems. The owner purchased the dog at the
age of 8 weeks. During the ﬁrst year of its life, the dog received
behavioral training and showed no signs of abnormal behavior. At
the age of 1 year, the dog started to show aggression combined with
Table 1
Results obtained by both the questionnaires
Behavioral outcome Baseline 1st rTMS treatment 2nd rTMS treatment
Training and obedience 3.50 3.13 3.25
Owner-directed aggression 0.00 0.00 0.00
Stranger-directed aggression 3.20 2.70 2.80
Dog-directed aggression/fear 2.63 2.13 2.25
Familiar dog aggression 0.00 0.00 0.00
Chasing 2.50 2.00 2.00
Stranger-directed fear 0.75 0.75 0.75
Nonsocial fear 0.67 0.83 0.17
Separation-related problems 0.88 0.13 0.5
Touch sensitivity 0.50 0.75 0.75
Excitability 1.83 1.83 0.83
SAIR 2 0 1
AIR 8 0 2.5
Reactivity 0.33 0.18 0.24
Severity 0.11 0.06 0.12
Intensity 4.33 3 4.75
SAIR, separation anxiety intensity ranks; AIR, anxiety intensity rank; rTMS, repeti-
tive transcranial magnetic stimulation.
A decrease in stranger- and dog-directed aggression, SAIR, AIR, reactivity, and
severity was noticeable.
Bold indicates a behavioral outcomes that were discussed in the Result section and
showed a decrease.
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miliar people or when separated from the owner). The aggression
started outmildly and evolved toward attempting to bite people and
dogs without apparent warning signs. Most of the aggressive
behavior was seen while walking with the dog. Indoors, no aggres-
sionwas seen against its owners or the other dog living in the house.
Aggressive behavior was ﬁrst seen toward other dogs, followed by
bikes and cars, and ﬁnally toward humans. Before the appearance of
its aggressive behavior, no behavioral signs (snarling, barking,
growling), with the exception of ﬁxation toward a close or distant
person or object, were seen. Once ﬁxated onto the person or object,
thepatientwould approach this target. Thedog sometimesbarkedat
theobjectorpeoplebefore its aggressivebehavior,when itwas in the
presence of the other dog. The dog also barked at people passing by
the owner’s house. Two biting incidents took place, during which
physical harm was caused to a person. As a reaction toward its
aggressive behavior, the owner trained the dog to bite when asked.
After that behavioral training, thedoghasbeenable to release its bite
when asked by the owner. Besides this training, no treatments
(behavioral or pharmaceutical) were administered.
Physical evaluation
After thoroughclinicalexamination,noclinicalabnormalitieswere
found. The dog’s blood analysis showed no deviations from the norm.
A 3 tesla magnetic resonance imaging showed no visible structural
abnormalities in the dog’s brain, whereas a functional d,1 hexame-
thylpropylene amine oxime single-photon emission computed to-
mography ([99mTc]HMPAO-SPECT) showed a decreased left frontal
perfusion (when compared with a control group). The control group
consisted of 16 healthy dogs ranging from 1 to 8 years old.
Behavioral evaluation
The dog’s behavior was assessed using the validated canine
behavioral questionnaire completed by the owner (Hsu and Serpell,
2003; Duffy and Serpell, 2012), providing information concerning
the dog’s behavior and temperament in 13 scales (Table 1). This
questionnaire contains 101 questions grouped into seven sections:
training and obedience, aggression, fear and anxiety, separation-
related behavior, excitability, attachment and attention seeking,
and miscellaneous. The responses to the questions were scored
with a 5-point frequency scale or a 5-point semantic differential
scale. Based on Table 1, the dog proved to be highly trained and
obedient and showed no aggressive behavior toward the owners or
familiar dogs. On the other hand, the dog scored high in the sections
stranger-directed aggression and dog-directed aggression/fear.
The owner was asked to complete a second questionnaire (see
Supplementary Files) that allowed insight into the dog’s reaction
toward the owner’s absence (actual and virtual) and noises including
(1) thunderstorm, (2) gunshots, (3) ﬁreworks, and (4) other noises
(Overall et al., 2001;Overall, 2013;Overall et al., 2016; Scheifele et al.,
2016). Responses toward these questions were (1) yes, (2) no, (3)
unknown. If “yes” was answered, the owner was asked to estimate
the frequency of the dog’s reaction toward the stimulus. The owner
could choice among the frequencies (1) 100% of the time, (2)<100 %
of the timebut>60%, (3) 40% to 60%of the time, (4) 0% of the timebut
<40%. In addition, the owner was asked to specify his dog’s reaction
and frequency of exposure to each noise. Possible reactions were
salivate, hide, defecate, tremble, urinate, vocalize, destroy, pace,
escape, freeze, will not eat food, pupil dilation, and/or pant. Answers
to the frequency of exposure were (1) never, (2) occasionally/once a
month, (3) regularly/a few times a month, (4) frequently/multiple
times a week. Based on questions from this section, a global separa-
tion anxiety intensity rank (SAIR) and anxiety intensity rank (AIR)were calculated. These were calculated based on the portrayed
behaviormultipliedbyaweightof4, 2.5,1.5,1, and0 for the frequency.
The maximum score for the SAIR and AIR was 48 and 208, respec-
tively. The second questionnaire included an aggression screen to
assess the dog’s reactivity, severity, and intensity toward several
stimuli (51). Reactivity was deﬁned as the proportion of stimuli to
which the dog reacts compared with the total number of listed
stimuli. To calculate the severity, the owner was asked to tick off his
dog’s response toward various stimuli. Possible reactionswere (1) no
reaction, (2) snarl, (3) lip lift, (4) bark, (5) growl, (6) snap, (7) bite, (8)
withdraw or avoid, and (9) not applicable. The speciﬁc behaviors
received a weight factor of 1 (barking and growling), 2 (snarling and
lip lifting), or 4 (snapping and biting). The severity of the dog’s
behavior was calculated by dividing the total reaction score (sum-
mationof all theweight factors) by total numberof possible reactions
toward all stimuli (9  51). Intensity was obtained by dividing the
total reaction score with the total number of stimuli (51).
Diagnosis
Based on the dog’s history, the physical examination, the MRI
images, the 99Tc-HMPAO SPECT scan, and the questionnaires, the
dog was diagnosed with anxious aggressive behavior speciﬁcally
toward nonfamiliar people and animals.
Treatment
Neuronavigation protocol
Neuronavigation is a technique whereby three-dimensional in-
formation about neurological structures enclosed by the skull or the
vertebral column is provided. This study focuses on the noninvasive
stimulation of the left frontal cortex. Therefore, the left frontal
cortex had to be externally located with neuronavigation. To obtain
this information, a tomographical data set (MRI) had to be acquired.
The neuronavigation and external localization was performed as
described by Dockx et al. (2017).
[99mTc]HMPAO-SPECT scan
The patient underwent four [99mTc]HMPAO-SPECT scans. A
baseline, one 24 hours, and one three weeks after the last
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ulation (aHF-rTMS) session were given. Two days after the last
SPECT scan, the aHF-rTMS treatment was again applied over the left
frontal cortex. Three weeks after the last session of the second
protocol, the patient received another [99mTc]HMPAO-SPECT scan.
Twenty-four hours before each SPECT scan, a 99Mo generator
was eluted and approximately 1.85 GBq 99mTcO4 was added to the
exametazime (HMPAO; Ceretec, GE Healthcare LTD, UK). The dog
was ﬁrst muzzled and intramuscular premedicated with dexme-
detomidine (375 mg/m2 body surface).When sedated, an IV catheter
was placed in a cephalic vein and on average 357.27 MBq (standard
deviation ¼ 54.62 MBq of [99mTc]HMPAO) was intravenously
injected. After 15-20 minutes, propofol was intravenous (IV)
administered to induce general anesthesia and was maintained
with isoﬂurane in oxygen through a rebreathing system. The dog
was monitored for respiratory and electrocardiographic function
throughout the scan. A triple-head gamma camera (Triad, Trionix,
Twinsburg, OH, USA), equipped with low-energy ultrahigh-reso-
lution parallel hole collimators (tomographic resolution full width
at half maximum ¼ 9 mm), was used to acquire the data. The
camera collected data over a circular 360 rotation in a step-and-
shoot mode during 20 minutes (120 steps, 10 sec per step, 3
steps) on a 128e128 matrix. Afterward, the data were iteratively
reconstructed and a Butterworth ﬁlter (cutoff, 1.4 cyclic/cm; order
5) was applied.
After the acquisition of the images, a template containing 11
brain regions (volumes of interest [VOIs]) (frontal, temporal, pari-
etal, and occipital lobes, the cerebellum, olfactory bulb, and the
subcortical area) was ﬁtted onto the data set using BRASS software
(Brain Registration and Automated SPECT Semiquantiﬁcation, Nu-
clear diagnostics, Sweden). The regional cerebral blood ﬂow (rCBF;
perfusion index) was obtained semiquantitatively (normalization of
the regional activity to the radioactivity of the entire brain).
A Z-score was obtained for each VOI at each time point with
SPECT images of healthy dogs ranging from 1 to 8 years old (control
group). The Z-score was calculated using the following equation: Z-
score ¼ ([mean control group] e [value patient])/(standard devia-
tion control group). The cutoff value was at jZj > 3.09 (comparable
to a P-value of 0.001), indicating signiﬁcant differences in the rCBF
when compared to the control group.
Peripheral and central monitoring of the monoaminergic system
Immediately after each [99mTc]HMPAO-SPECT scan, cerebrospi-
nal ﬂuid (CSF) and serumwere acquired. The CSF tapwas performed
at the cisterna magna using a 19 G needle after the patient was
positioned in right lateral recumbency. While still under anesthesia
and right lateral recumbency, a 21G needle was used to draw blood
fromthevenajugularis externa. Anantioxidativemixturecontaining
0.1 M perchloric acid (Merck, Darmstadt, Germany), 0.05% Na2EDTA
(Sigma Aldrich, Saint Louis, USA), and 0.05% sodium metabisulﬁte
(Merck, Darmstadt, Germany) was made. 900 mL and 25 mL of this
mixture were added to 100 mL serum and 100 mL CSF, respectively.
The diluted samples were immediately frozen (80 Celsius) until
further analysis. Before the analysis, the samples were thawed and
centrifuged at 15000 rpm for 15 minutes. The supernatant was
transferred and diluted 1/2 (CSF) and 1/5 (serum) with 0.5 M acetic
acid (Fisher scientiﬁc, Bishop Meadow road, UK).
Total noradrenaline, dopamine (DA), 3,4-dihydroxyphenylacetic
acid (DOPAC), 4-hydroxy-3-methoxyphenylacetic acid (homo-
vanillic acid [HVA]), serotonin, and 5-hydroxyindoleacetic acidwere
measured in CSF and serum based on previously reported methods
(El Arfani et al., 2014; Jardi et al., 2018). The samples were injected
automatically on a reversed-phase liquid chromatography system
(autosampler ASI-100 and HPLC pump P680 A HPG/2, Dionex,Amsterdam, The Netherlands) with electrochemical detection
(potential¼þ 700mV) (AmperometricDetector LC-4C, BAS, Indiana,
USA). The separationwas achieved using a narrowbore C18 column
(Alltech, AlltimaTM, 5 mm,150 2.1 mm, Grace, Deerﬁeld, IL, USA).
The mobile phase buffer contained 0.1 M sodium acetate (Carl Roth
GmbHþ Co, Karlsruhe, Germany), 20mM citric acid (Sigma Aldrich,
Saint Louis, USA), 1 mM sodium octane sulfonic acid (Carl Roth
GmbH þ Co, Karlsruhe, Germany), 1 mM dibutylamine (Sigma
Aldrich, Saint Louis, USA), and 0.1 mM Na2EDTA adjusted to pH 3.7
(mobile phase composition: 97 buffer/3methanol [v/v]). The sample
concentration was expressed as ng monoamine/100 mL.
rTMS treatment
The aHF-rTMS treatment was applied, under general anesthesia,
twice (three weeks separated). The dog was muzzled, a cephalic
catheter was placed, and butorphanol was IV administered (0.2 mg/
kg; Dolorex; Intervet Belgium NV). When sedated, the dog was
given midazolam IV (0.2 mg/kg; Dormicum; Roche Nederland
BV). This was immediately followed by IV injection of propofol (1-
2 mg/kg given to effect) to induce general anesthesia. Because it
was chosen to set the stimulation intensity of the treatment based
on the excitability of the motor cortex, the cortical motor threshold
(CMT) of the left motor cortex was determined. After the induction
of the general anesthesia, the spot for determining the CMT was
identiﬁed as the cortical area that provoked the clearest muscular
contraction in the right proximal front limb. Once the hotspot was
identiﬁed, the machine output (The Magstim Company Limited)
was set at an intensity that provoked 100% of muscular twitches.
This output was stepwise decreased with 5%, 2%, and 1% until ﬁve of
10 consecutive pulses induced a visible muscular twitch (Rossini
et al., 2015).
Once the measurement of the CMT was ﬁnished, the center of
the left frontal cortex, based on the topographical information from
the neuronavigation, was identiﬁed with a marker on the fur. The
center of a standard ﬁgure-of-eight coil was placed over the mark
with the handle pointing abaxial. The applied aHF-rTMS protocol
consists of ﬁve sessions (frequency ¼ 20 Hz, intensity ¼ 110% CMT).
A waiting period of 12-15 minutes was set between two sessions.
Each session held 40 trains (12-second intertrain interval) during
1.9 seconds each. In total, 1560 pulses were given per session. This
protocol is also used clinically and experimentally at our medical
university hospital (Baeken et al., 2013; Baeken et al., 2015).
Behavioral assessment
After applying each aHF-rTMS treatment, the owner was asked
to ﬁll in the canine behavioral questionnaire and the questionnaire
focusing on separation anxiety, noise phobia, reactivity, and
aggression. Because clinical improvement of an rTMS treatment is
mostly seen within 2 to 6 weeks, the owner was asked to ﬁll in the
questionnaires 3 weeks after the last rTMS session was given
(O’Reardon et al., 2007; Feffer et al., 2018).
Follow-up
The owner noticed behavioral changes two to three weeks after
the ﬁrst stimulation session. The most prominent reported change
was a reduction of the ﬁxation onto persons, dogs, or objects. Even
more, a reduction in aggressive behavior toward unfamiliar dogs,
humans, and objects was noticed several weeks after the second
aHF-rTMS protocol was administered. The owner reported that the
dog did no longer show the urge to approach the person or target it
had seen. This was in sharp contrast to its initial behavior. Even
more, the dog stopped portraying avoidance behavior when a
Table 3
Concentrations (ng/100 mL) of the investigated monoamines and their metabolites
measured with liquid chromatographydelectrochemical detection
Monoamine Baseline 24 h 3 wk 6 wk
Serum
NAD 3.62 4.55 4.16 6.23
DA ND ND ND ND
DOPAC 26.39 122.41 33.067 27.90
HVA 30.63 42.86 24.72 29.79
5-HT 21.59 18.62 29.97 25.17
5-HIAA ND ND ND ND
CSF
NAD 1.45 1.63 1.54 -
DA ND ND ND -
DOPAC 0.16 0.49 0.25 -
HVA 12.57 19.40 12.70 -
5-HT ND ND ND -
5-HIAA 2.20 3.70 2.35 -
NAD, noradrenaline; DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA,
homovanillic acid; 5-HT, serotonin; 5-HIAA, 5-hydroxyindoleacetic acid; ND, not
detected; CSF, cerebrospinal ﬂuid.
-, missing value due to CSF contaminated with blood.
Bold indicates a behavioral outcomes that were discussed in the Result section and
showed a decrease.
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while eating or playing with a toy, and when approached by a
human or other dog when sleeping. The canine behavioral assess-
ment and research questionnaire revealed a positive improvement
of the dog’s aggressive behavior toward strangers and dogs
(Table 1). The second questionnaire indicated a decrease in dog’s
SAIR, AIR, and reactivity (Table 1). No aversive effects were noticed.
At baseline, a signiﬁcant lower rCBF at the left frontal cortex was
noticeable (Z-score¼3.87). Twenty-four hours after the ﬁrst aHF-
rTMS treatment was applied, the rCBF of the left frontal cortex did
not differ any longer from the mean rCBF of the control group (Z-
score ¼ 0.04). At this time point, the mean of patient’s subcortical
regionwas signiﬁcantly lower than themeanof the control group (Z-
score¼6.97). Three weeks after the ﬁrst aHF-rTMS treatment was
applied, the rCBF of the left frontal cortex remained comparable to
the rCBF of the control group (Z-score ¼ 0.58) (Table 2). Three
weeks after the second stimulation session, nodeviations in the rCBF
were found when compared with the control group (Table 2).
The CSF showed mild increases in the concentration of 5-
hydroxyindoleacetic acid 24 hours after the ﬁrst aHF-rTMS treat-
ment was given (Table 3). In both CSF and serum, DOPAC and HVA
increased 24 hours after the aHF-rTMS treatment (4 times baseline
value). Three weeks after each treatment, the DOPAC and HVA
concentrations decreased again to almost baseline value (Table 3).Discussion
This study showed that an aHF-rTMS treatment applied over the
left frontal cortex induced not only changes in the cerebral perfu-
sion at the simulation site but also at remote locations as well.
These changes lasted at least 3 weeks and were accompanied by
improvement of the dog’s behavior. Even more, simultaneous
changes of DOPAC concentrations in CSF and serumwere observed.
The patient had, at baseline, a hypoperfused left frontal cortex
and showed anxious aggressive behavior toward people and ani-
mals. Hereby, this study conﬁrmed that canine anxiety is associated
with a hypoperfusion of the left frontal cortex Vermeire et al. (2009).
The patient’s impaired frontal perfusion might have led to a higher
emotional state (anxious) and a loss of drive inhibition (aggressive
behavior) (Brutkowski, 1965; Dabrowska, 1971; Konorski, 1973).
After applying aHF-rTMS over the left frontal cortex, the patient’s
rCBF of the frontal cortex normalized,whichwas accompanied byan
improvement of his aggressive behavior. However, the patient’s
subcortical region showed, at baseline, no perfusion abnormalities.
Nonetheless, directly after each stimulation protocol, the perfusion
of the subcortical region (including a large part of the emotion-
steering limbic system) decreased signiﬁcantly (Table 2). This
remote effect of the aHF-rTMS treatment conﬁrms the connectivity
between the frontal cortex and the subcortical region, moreTable 2
Z-values for each VOI at each time point
Brain region Baseline 24 h 3 wk 6 wk
Left temporal 0,65 0,29 1,63 1,05
Right temporal 1,00 0,40 1,40 1,16
Cerebellum 0,57 0,79 0,75 1,70
Subcortical 0,24 6,97a 0,54 0,77
Bulbus olfactorius 0,56 0,88 0,21 1,26
Left frontal 3,87a 0,04 0,58 1,86
Right frontal 0,94 0,55 0,17 0,17
Left occipital 0,68 0,40 0,03 0,41
Right occipital 1,18 0,11 0,70 0,22
Left parietal 0,39 0,34 2,95 0,82
Right parietal 1,77 1,23 3,69a 2,14
VOI, volume of interest.
a jZ-valuej > 3.06 (equivalent P-value of 0.001).speciﬁcally, a functional connectivity with the thalamus and the
basal ganglia because the subcortical VOI consisted of these regions.
This was to be expected because of the presence of reciprocal pro-
jection ﬁbers between the frontal cortex and the mediodorsal nu-
cleus of the thalamus and between the thalamus and the basal
ganglia (Narkiewicz and Brutkowski, 1967; Hintzen et al., 2018).
These local and remote changes are in line with the ﬁndings in HF-
rTMS research in treatment-resistant depression (Catafau et al.,
2001; Loo et al., 2003; Knoch et al., 2006; Kito et al., 2008).
Furthermore, rTMS has been shown to induce an endogenous
increase of DA in the striatum dorsal hippocampus, nucleus cauda-
tus, and nucleus accumbens (Strafella et al., 2001; Keck et al., 2002;
Pogarell et al., 2006), members of the limbic system. This study
demonstrated that rTMS modulated the concentration of the DA
metabolites HVA and DOPAC in CSF after each treatment. It has been
reported that HVA concentrations in the CSF provide information of
theDA turnover in the striatum (Youet al.,1998;Kuhar et al.,1999). A
reason for the absence of a change inDAconcentration itself could be
the fact that the detection capacity of the test is suboptimal or a low
concentration of DA. In this study, serum and CSF were acquired
24 hours after the last stimulation session, whereas other studies
assessed the changes in DA directly after the last stimulation session
(Strafella et al., 2001; Keck et al., 2002; Strafella et al., 2003; Kanno
et al., 2004; Pogarell et al., 2006). This combined with the short
half-life of DA (Yavich et al., 2007) and the fact that free DA is
immediately broken down (monoamino oxidase, cathechol-O-
methyltransferase) could have led to the absence of DA changes in
the serum and CSF. Nonetheless, because HVA and DOPAC are DA
metabolites, an endogenous release of DA, after aHF-rTMS, over the
left frontal cortex in anxious aggressive dogs can be assumed. This
assumption is strengthened by the fact that prefrontal DA also plays
a role in the neuronal response to fear, anxiety, and stress (Pezze and
Feldon, 2004; Riva et al., 2008). Therefore, the neuromodulative
action of aHF-rTMS over the left frontal cortex in canine anxious
aggressiveness could be facilitated by a release of DA.
The increase of DOPAC in the serum could be twofold. The
DOPAC concentration increased in the blood together with its
concentration in the CSF coinciding with changes in the rCBF and
clinical improvement. Therefore, changes in the serum could
represent the changes in the CSF. Subsequently, peripheral DA could
serve as a valid biomarker to monitor the clinical response of an
anxious aggressive patient to an aHF-rTMS treatment. Second, DA is
also present outside the central nervous system (neuronal ﬁbers,
R. Dockx et al. / Journal of Veterinary Behavior 33 (2019) 108e113112adrenal medulla, and neuroendocrine cells) and its release is mostly
regulated by the sympathetic noradrenergic nerves (Goldstein and
Holmes, 2008; Rubi and Maechler, 2010). This combined with the
fact that rTMS can inﬂuence the autonomic nervous system
(Schestatsky et al., 2013) gives rise to the possibility that in this
study the serum DOPAC concentration was elevated through acti-
vation of the autonomic nervous system. Nonetheless, one would
assume a concurrent increase in noradrenaline, which was not
noted in this study.
A major limitation of this study is the number of included sub-
jects and the absence of a sham-controlled group. Questionnaires,
combined with functional and morphological imaging, were used
to assess the patient’s behavior. It has to be kept in mind that to
evaluate the behavioral improvement more precisely, regular con-
sultations with a small animal behavioral specialist should be
minimal requirement, preferably in a blinded placebo-controlled
experiment.
To conclude, a single-day aHF-rTMS treatment alters the local
and remote rCBF and is accompanied by an improvement of the
dog’s anxious aggressive behavior. An increase of the DOPAC con-
centration in the CSF and serum coincides with an improvement of
the patient’s pathological behavior. Therefore, DOPAC may be a
potential biomarker for treatment effects and also possibly for
clinical improvement.
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